At-risk esophageal adenocarcinoma patients or patients who already have Barrett’s esophagus.
- Brushing specimen in ThinPrep PreservCyt vial (for FISH and IHC)
- Transport at room temperature in brushing transport kit
Our panel of biomarkers that have known associations with dysplastic changes of Barrett’s esophagus includes:
- AMACR (P504S) – The concentration and activity of this protein has recently been identified as a useful biomarker in detecting dysplasia in ulcerative colitis, Crohn’s disease, and Barrett’s esophagus.
- p53 – The study of p53 expression by IHC is of interest in Barrett’s esophagus patients with a diagnosis of indefinite for dysplasia or low-grade dysplasia.
- Ki-67 – IHC staining for MIB-1, the Ki-67 proliferation antigen, appears gradually.
- ABPH 2.5 – Stains the acidic mucin present in goblet cells.
- Feulgen Stain – Used for the quantification of chromosomal material or DNA with sufficient resolution to detect the gain or loss of a single large chromosome.
- Cytology – Imparts a characteristic range of coloration to exfoliative cells, allowing critical examination of nuclei and cytoplasmic components.
FISH: Our FISH panel of biomarkers provides an indication of progression requiring additional procedures and specific management. Utilizing a four-probe panel to detect gains and losses of MYC (8q24), p16 (CDKN2A at 9p21), HER2 (ERBB2 at 17q12), and ZNF217 (20q13) associated with higher-risk disease, our Barrett’s FISH panel offers:
- Differentiation between patients with low-grade dysplasia and high-grade dysplasia.
- Histology confirmation when results are concordant, and suggests further investigation is needed when results differ from histology.
- Support for aggressive treatment decisions based on positive test results together with concordant morphology.